Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday October 28, 2009

DrStockPick.com Stock Report!

PWRM, STEM

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

PWRM, Power 3 Medical Products Inc, PWRM.OB

STEM, StemCells, Inc.

DrStockPick.com Report!

Dr Stock Pick HOT News & Alerts!

PWRM, Power 3 Medical Products Inc. and STEM, StemCells, Inc., Tracking

The Footprints of Disease

Thursday September 10, 2009

************************************************************** STEM, StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder

STEM is focused on the development and commercialization of cell-based technologies. In its therapeutic product development programs, STEM is targeting diseases of the central nervous system and liver. StemCells’ lead product candidate, HuCNS-SC® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that

PWRM, Power 3 Medical Products Inc, PWRM.OB

STEM, StemCells, Inc.

DrStockPick.com Report!

Dr Stock Pick HOT News & Alerts!

STEM, StemCells, Inc. and PWRM, Power 3 Medical Products Inc, Tracking

The Footprints of Disease

Wednesday September 9, 2009

************************************************************** STEM, StemCells, Inc.

STEM is focused on the development and commercialization of cell-based technologies. In its therapeutic product development programs, STEM is targeting diseases of the central nervous system and liver. StemCells’ lead product candidate, HuCNS-SC® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. STEM also markets specialty cell culture media

Raptor Pharmaceuticals Corp. is a development-stage biotechnology company with their corporate headquarters in Novato, California. They engage in the acquisition, development, and commercialization of pharmaceutical products in the United States. As an OTCBB-traded enterprise, they dedicate their efforts to speeding the delivery of new treatment options to patients. They do this by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise.

The company focuses on underserved patient populations. Their DR Cysteamine is an investigational, delayed-release (DR) oral formulation of cysteamine bitartrate. This is for the potential treatment of nephropathic cystinosis (cystinosis), which is a rare lysosomal storage disease. Raptor’s DR Cysteamine formulation may require less frequent dosing and reduce gastrointestinal side effects. They are also developing DR Cysteamine for the potential treatment of Non-alcoholic Steatohepatitis (NASH), Huntington’s Disease, and Batten Disease. Raptor is also in clinical development of Convivia™. They are developing

Raptor Pharmaceuticals Corp. is a development-stage biotechnology company with their corporate headquarters in Novato, California. They engage in the acquisition, development, and commercialization of pharmaceutical products in the United States. As an OTCBB-traded enterprise, they dedicate their efforts to speeding the delivery of new treatment options to patients. They do this by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise.

The Company focuses on underserved patient populations. Their DR Cysteamine is an investigational, delayed-release (DR) oral formulation of cysteamine bitartrate. This is for the potential treatment of nephropathic cystinosis (cystinosis), which is a rare lysosomal storage disease. Raptor’s DR Cysteamine formulation may require less frequent dosing and reduce gastrointestinal side effects.

The company is also developing DR Cysteamine for the potential treatment of Non-alcoholic Steatohepatitis (NASH), Huntington’s Disease, and Batten Disease. Additionally, Raptor is in clinical development of Convivia™ for the

Ceregene Inc. concentrates on the delivery of nervous system growth factors to treat neurodegenerative disorders using gene delivery. Specifically, the company created CERE-110 for the treatment of Alzheimer’s disease, which affects millions of people in the United States.

The company today announced the University of California, San Diego, has received a $5.4 million grant from the National Institute of Aging at the National Institutes of Health to support Ceregene’s phase II clinical study of CERE-100.

“We are pleased to be involved in evaluating CERE-110 which we believe may be a promising therapy for Alzheimer’s disease,” Paul Aisen, M.D., principal investigator of the planned phase 2 trial and director of the Alzheimer’s Disease Cooperative Study at University of California, San Diego, stated in a press release. “Over five million people in the U.S. are currently living with Alzheimer’s disease — a disease which is devastating to patients and their families —